A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip?

This is no reason to panic.

EU Committee Backs Extending Use of Lilly's Diabetes Drug for Children Aged 10 and Above

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ...

Market voices: Lilly's new obesity drug, Bessent, EQT's robotics move

Eli Lilly (LLY) said that a late-stage study showed its new injected medication retatrutide helped obese patients lose up to ...

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...